Approaching MRD in Multiple Myeloma


At the 2020 Great Debates and Updates in Hematologic Malignancies Meeting in Los Angeles, Thomas Martin, MD, the University of California, San Francisco, discussed the evolution of minimal residual disease testing in MM and whether or not it is ready for prime time.

12 + 6 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Stay in the know.
OncNet Newsletter